TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00392951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)
Study: NCT03215745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delirium prevention program
Description: Delirium prevention program Placard with the names of the care team and the calendar days; cognitively stimulating activities three times a day. Pictures, radio, robe. Visual aids large print books, with daily reinforcement of use Maintain adequate lighting opening blinds and curtains during the day, and darken their environment at night. Dissipation wax and special techniques of communication, with daily reinforcement of these adaptations. Go to the patient by name and tone of voice appropriate. Always listen. Use simple and clear language, face-to-face. Avoid excessive familiarity and childish. Promote family involvement in self-care and caregivers and the reorientation of the patient, contact with extended family during the stay.
Study: NCT00636155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cenersen sodium
Description: 2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 on day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m2 on days 2, 3, and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 on days 2, 3, and 4
Study: NCT04383964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distraction Osteogenesis for Reconstruction of Ramus-Condyle
Description: transport distraction osteogenesis in restoring the deficient condyle/ramus unit of patients with TMJ ankylosis to correct the resultant deformity either unilaterally or bilaterally.
Study: NCT01446991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: 240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: 240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
Study: NCT00782106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase + immune globulin intravenous
Description: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase + immune globulin intravenous
Description: 1. IV infusion of IGIV, 10% to determine pharmacokinetics~2. Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
Study: NCT02852291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents Make the Difference
Description: 10 parent training sessions delivered to groups of caregivers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents Make the Difference Plus
Description: 10 parent training sessions delivered to groups of caregivers, with 3 home visits
Study: NCT00551967

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip replacement
Description: Surgical implantation of hip replacement components for the treatment of osteoarthritis
Study: NCT03828565

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ScvO2 Perioperative continue monitoring
Description: ScvO2 Perioperative continue monitoring with PreSep® system. If SvcO2 is less than 65% or decreases by more than 10% of its base value, the other parameters affecting ScvO2 (BIS (40-60% objective), Hb (objective\> 8g / dL), SaO2 (objective\> 94%)) are evaluated. If, after correcting for these parameters, the ScvO2 is not corrected, the preload-dependence parameters are evaluated (variation of the pulsed pressure) to guide the vascular filling: VF of 250 mL of crystalloids if PPV\> 13%, norepinephrine if PPV\<9%, reassess if PPV between 9 and 13%.~If VF or norepinephrine does not correct ScvO2 (\> 65%), a measurement of arterial lactate is performed. If lactatemia is\> 2 mmol / L, a positive inotrop is introduced after ETO if possible. If lactatemia is \<2 mmol / L, a return to the evaluation phase of the parameters influencing ScvO2 is necessary.
Study: NCT02907411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadrivas Therapy
Description: Quadrivas therapy will be applied to subjects. Quadrivas therapy is a intensive massage therapy for different tissues. Subjects will receive 12 treatments. The first lasting 2.5 hours and the remaining 11 lasting 1.5 hours.
Study: NCT02669446

Intervention type: DEVICE
Intervention: Medical devices

Intervention type: DEVICE
Intervention: Medical devices

Intervention type: DEVICE
Intervention: traditional household remedy
Study: NCT01868594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subetta
Description: Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Study: NCT01969305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kazakhstani Family Together
Description: Adolescent-caregiver pairs will receive three 45-minute interactive multi-media sessions with avatars customized to participants' gender that will focus on risk reduction self-efficacy, resistance to peer pressure, decision-making skills and caregiver-adolescent communication, support and monitoring to strengthen youth's relationships with caregivers and reduce youth's risks of drug use and sexual risk behaviors. Through the multimedia tool, participants will confront a series of sexual risks and substance use related situations and will practice their listening, empathy, assertiveness, refusal, and other interpersonal skills. Each caregiver-youth pair will work jointly and engage in discussions, exercises, and behavioral rehearsal as directed by the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care Alone
Description: Adolescents from both study arms will receive the usual care, a health education program about how to prevent drug use and HIV/STIs (sexually transmitted infections). The health education curriculum is delivered in a group format by trained peer educators and outreach workers. The curriculum consists of three 45-minute sessions that include lectures and interactive quizzes about drugs and HIV. These three sessions include information on the following topics:~1. Facts and Myth about HIV. HIV/STIs modes of transmission;~2. Prevention of HIV. Abstinence and Safe Sex. Attitudes and values about sexuality, sexual risk behaviors, and condom use;~3. Knowledge, attitudes and beliefs about drinking and drug use. Risks and consequences of drug use.
Study: NCT02256345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KNO3
Description: Active Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KCl
Description: Placebo Comparator
Study: NCT02907801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perception-Action Approach
Description: Environmental set-up, gentle manual guidance, and caregiver education
Study: NCT01542294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: s1
Description: 60-90mg/m2/d P.O. day 1-14, repeated every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 d1 repeated every 21 days
Study: NCT03288311

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized post-extubation respiratory support
Description: Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
Study: NCT00005577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT02349776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing testimonies from survivors of transplants to patients
Description: Patients will be asked to complete one mood measure (the HADS), the Life Orientation Test (LOT), and a questionnaire about expectations of treatment in clinic once a decision to proceed to transplant has been made.~Patients will receive the testimonies upon admittance to the transplant unit and then receive the HADS and a structured interview within the first week of being admitted to the transplant ward (just prior to receiving the transplant) and within the first two weeks following the transplant.
Study: NCT00691054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4. Treatment cycles will be repeated every 28 days for as long as disease is not progressing and patient tolerates treatment
Study: NCT00515554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: addition of Rituximab to BEACOPP escalated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEACOPP escalated
Description: chemotherapy with BEACOPP escalated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPP escalated
Description: chemotherapy with BEACOPP escalated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEACOPP escalated
Description: chemotherapy with BEACOPP escalated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPP escalated
Description: chemotherapy with BEACOPP escalated
Study: NCT02444806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full polysomnography
Description: Full sleep and respiratory monitoring with EEG

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oximetry-capnography
Description: Limited monitoring with nurse observation and continuous oximetry-capnography overnight for NIV titration.
Study: NCT00096824

Intervention type: BEHAVIORAL
Intervention: Neurological assessment
Description: All participants will undergo neurological examinations and neuropsychological assessments.
Study: NCT01739374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reduced mesh implants
Description: mesh for pelvic floor reinforcement
Study: NCT03746145

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum 1714
Description: This is a double-blind randomized placebo-controlled pilot study. Participants under extreme conditions of hypoxia, confinement and isolation receive Bifidobacterium longum 1714 on a daily basis over one year in order to test improvements on stress resilience and immune functions.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo sachet containing maltodextrin and magnesium stearate.
Description: placebo sachet containing maltodextrin and magnesium stearate.
Study: NCT02296905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.
Study: NCT02299700

Intervention type: OTHER
Intervention: No Intervention
Description: The usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in Autism Spectrum Disorder (ASD) will be observed.
Study: NCT02314156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telapristone Acetate
Description: Given PO
Study: NCT04810949

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamine D3 supplementation
Description: 1. The supplementation treatment will consist of prescribing vitamin D3 consumption of 4000 U 13 single dose tablets each month (52,000 IU).
Study: NCT02314156

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given transdermally
Study: NCT04810949

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet and sun exposure
Description: 2. Hygienic-dietary recommendations will consist of 2 steps~1. Sun exposure at least 10 minutes a day from 10: 00-6: 00 pm~2. Consumption of foods rich in vitamin D: milk, fish, almonds, mushrooms
Study: NCT02459535

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stimulation glucose
Description: oral stimulation with glucose, AS or glucose+AS in fasted state, blood samples from fasted state up to 120 min post-ingestion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stimulation glucose
Description: oral stimulation with glucose, AS or glucose+AS in fasted state, blood samples from fasted state up to 120 min post-ingestion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stimulation glucose
Description: oral stimulation with glucose, AS or glucose+AS in fasted state, blood samples from fasted state up to 120 min post-ingestion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stimulation glucose
Description: oral stimulation with glucose, AS or glucose+AS in fasted state, blood samples from fasted state up to 120 min post-ingestion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stimulation saccharin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stimulation saccharin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stimulation aspartame

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stimulation aspartame

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stimulation sucralose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stimulation sucralose
Study: NCT01807286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Phase I: Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21 of a 28 day cycle.~Phase II: Starting dose of Pomalidomide maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Phase I and II: 9 mg/m2 by mouth on days 1-4 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Phase I and II: 40 mg/day by mouth on days 1-4 of a 28 day cycle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires about the feeling in hands and quality of life completed at different time points during the study.
Study: NCT00471289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTA with placement of paclitaxel-eluting stent
Description: PTA with placement of paclitaxel-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA
Description: PTA
Study: NCT03666650

Intervention type: DRUG
Group type: OTHER
Intervention: Edoxaban 60 MG
Description: Viscoelastic analysis and standard laboratory tests after edoxaban ingestion
Study: NCT03204708

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter
Description: catheter was placed under clavipectoral fascia by open technique by surgeon at the 1/3 lateral part of clavicula neighbourhood of nervus thoracicus longus, nervus thoracodorsalis, nervus pectoralis lateralis, nervus pectoralis medialis
Study: NCT02299700

Intervention type: OTHER
Intervention: No Intervention
Description: The usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in Autism Spectrum Disorder (ASD) will be observed.

Intervention type: OTHER
Intervention: No Intervention
Description: The usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in Autism Spectrum Disorder (ASD) will be observed.
Study: NCT02744014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Add-on Therapy for Axial Spondyloarthritis

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Add-on Therapy for Axial Spondyloarthritis
Study: NCT02309502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green Pascal
Description: Single-session Barely Visible Pascal 532nm 3,000 burns 20ms Multi-spot, single session~Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: 100%~Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yellow Pascal
Description: : Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management: 70% Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: A barely visible burn will be aimed at for the pattern landmark burns and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants
Study: NCT01250301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-nicotinised cigarettes + standard treatment
Description: Participants will receive de-nicotinised cigarettes to use as required for 2 weeks after their quit day. These cigarettes are intended to provide a replacement for the behavioural and sensory aspects of smoking without supplying nicotine.~Participants will also receive standard NHS Stop Smoking Service treatment. This is a combination of weekly behavioural support and medication (e.g. nicotine replacement therapy/varenicline).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Participants will receive standard treatment from the NHS Stop Smoking Service.
Study: NCT02314156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03204708

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter
Description: catheter was placed under clavipectoral fascia by open technique by surgeon at the 1/3 lateral part of clavicula neighbourhood of nervus thoracicus longus, nervus thoracodorsalis, nervus pectoralis lateralis, nervus pectoralis medialis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv analgesia
Description: patients were given 100 ml of tramadol 30 minutes before extubation
Study: NCT04277052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Determination muscles sections by Ultrasonography
Description: Determination muscles sections by Ultrasonography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Determination muscles sections by Ultrasonography
Description: Determination muscles sections by Ultrasonography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Determination muscles sections by Ultrasonography
Description: Determination muscles sections by Ultrasonography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Determination muscles sections by Ultrasonography
Description: Determination muscles sections by Ultrasonography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Determination muscles sections by Ultrasonography
Description: Determination muscles sections by Ultrasonography
Study: NCT03551106

Intervention type: OTHER
Intervention: Web based learning module
Description: Web based learning module available on a especially designed website
Study: NCT00833885

Intervention type: DEVICE
Group type: OTHER
Intervention: Masks
Description: Wearing of surgical masks

Intervention type: DEVICE
Group type: OTHER
Intervention: Masks & hand hygiene
Description: Wearing of surgical masks and intensified hand washing

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: General information about virus transmission in households and basic means to prevent it
Study: NCT01163045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thyroidectomy
Description: total thyroidectomy and lobectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thyroidectomy
Description: total thyroidectomy and lobectomy
Study: NCT01754610

Intervention type: BEHAVIORAL
Intervention: Strengthening Family Coping Resources (SFCR)
Description: Trauma Version (15 weeks) and High Risk Version (10 weeks) are 2 hour sessions. Dinner will be provided at the start of group for all participants.~Activities will be conducted at each group to encourage family involvement. The treatment modules focus on family rituals and routine, strengthening families' collaborative coping, and resolution of the trauma(s) bringing the families to treatment. Activities will be both family-based and age-based.